7465EA24-534F-45A3-8CD3-AD985E574BFF
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 14.388961892247043
- age_years
- 26
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.567
- CHOLESTEROL_HOMEOSTASIS+0.480
- MYC_TARGETS_V1+0.473
- DNA_REPAIR+0.470
- E2F_TARGETS+0.447
- G2M_CHECKPOINT+0.409
- OXIDATIVE_PHOSPHORYLATION+0.408
- WNT_BETA_CATENIN_SIGNALING+0.404
- MTORC1_SIGNALING+0.320
- NOTCH_SIGNALING+0.320
Top 10 suppressed
- KRAS_SIGNALING_DN-0.318
- SPERMATOGENESIS-0.277
- MYOGENESIS-0.230
- COAGULATION-0.216
- INFLAMMATORY_RESPONSE-0.212
- TNFA_SIGNALING_VIA_NFKB-0.196
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.188
- UV_RESPONSE_DN-0.168
- HYPOXIA-0.167
- IL6_JAK_STAT3_SIGNALING-0.155
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | D837BDD1-8786-4548-8D5F-8506AECF2006 | — | — | 0.913 |
| 2 | 913D6292-6507-4F86-A120-137CEACE5C9F | — | — | 0.906 |
| 3 | 7E7AAFFD-6EEB-4357-88AD-9EB12BB78602 | — | — | 0.899 |
| 4 | 46AD8592-A823-48DA-AB51-3CEC34F53E04 | — | — | 0.896 |
| 5 | F9FA52F2-BD53-4CE8-B227-5936AE06B76A | — | — | 0.889 |
| 6 | 83BB732E-132F-4677-B70D-5ADE69831226 | — | — | 0.889 |
| 7 | D0F8B6CA-5F3B-4B66-BCC5-72C17325DABF | — | — | 0.887 |
| 8 | 111625A4-390B-4D8C-BF80-020062CE9D89 | — | — | 0.870 |
| 9 | 37DF227E-8B22-4757-A65C-87C6F28F87D4 | — | — | 0.863 |
| 10 | 840B7494-6E8E-4518-874A-0C98EF0CBB72 | — | — | 0.863 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.567 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.480 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.473 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.470 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.447 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.409 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.408 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.404 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.320 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.320 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.311 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.305 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.290 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.223 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.216 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.206 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.202 | Cobimetinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.200 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.190 | Inavolisib | — uncovered |
| PEROXISOME | 0.156 | Idelalisib | — uncovered |